company background image
BIOQ

Bioqual OTCPK:BIOQ Stock Report

Last Price

US$81.80

Market Cap

US$73.2m

7D

0%

1Y

-9.1%

Updated

06 Feb, 2023

Data

Company Financials

BIOQ Stock Overview

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.

BIOQ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends3/6

My Notes

New

Notes are coming soon

Bioqual, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bioqual
Historical stock prices
Current Share PriceUS$81.80
52 Week HighUS$96.00
52 Week LowUS$57.00
Beta-0.17
1 Month Change0%
3 Month Change12.05%
1 Year Change-9.11%
3 Year Change75.91%
5 Year Change121.98%
Change since IPO27,165.58%

Recent News & Updates

Recent updates

Shareholder Returns

BIOQUS Life SciencesUS Market
7D0%1.7%1.7%
1Y-9.1%-11.2%-9.6%

Return vs Industry: BIOQ exceeded the US Life Sciences industry which returned -11.2% over the past year.

Return vs Market: BIOQ matched the US Market which returned -9.6% over the past year.

Price Volatility

Is BIOQ's price volatile compared to industry and market?
BIOQ volatility
BIOQ Average Weekly Movementn/a
Life Sciences Industry Average Movement11.7%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: Insufficient data to determine BIOQ's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine BIOQ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1981n/aMark Lewishttps://www.bioqual.com

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.

Bioqual, Inc. Fundamentals Summary

How do Bioqual's earnings and revenue compare to its market cap?
BIOQ fundamental statistics
Market CapUS$73.16m
Earnings (TTM)US$5.42m
Revenue (TTM)US$67.96m

13.5x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOQ income statement (TTM)
RevenueUS$67.96m
Cost of RevenueUS$50.79m
Gross ProfitUS$17.18m
Other ExpensesUS$11.76m
EarningsUS$5.42m

Last Reported Earnings

Nov 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)6.06
Gross Margin25.27%
Net Profit Margin7.98%
Debt/Equity Ratio54.4%

How did BIOQ perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

17%

Payout Ratio